Amanote Research
Register
Sign In
Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
Cancers
- Switzerland
doi 10.3390/cancers11111642
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
October 24, 2019
Authors
Unknown
Publisher
MDPI AG
Related search
Tolerability of BRAF/MEK Inhibitor Combinations: Adverse Event Evaluation and Management
ESMO Open
Cancer Research
Oncology
Why Do We Need a New BRAF-MEK Inhibitor Combination in Melanoma?
Oncology in Clinical Practice
Oncology
Efficacy and Safety of BRAF Inhibition Alone Versus Combined BRAF and MEK Inhibition in Melanoma: A Meta-Analysis of Randomized Controlled Trials
Oncotarget
Oncology
Combination Therapy With BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy
Therapeutic Advances in Medical Oncology
Oncology
Inhibitors of Pan-Pi3k Signaling Synergize With BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
Frontiers in Oncology
Cancer Research
Oncology
Erratum: Mechanism of MEK Inhibition Determines Efficacy in Mutant KRAS- Versus BRAF-driven Cancers
Nature
Multidisciplinary
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
Frontiers in Oncology
Cancer Research
Oncology
Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma
Molecular Cancer Therapeutics
Cancer Research
Oncology
Comparative Efficacy of Combination Immunotherapy and Targeted Therapy in the Treatment of BRAF-mutant Advanced Melanoma: A Matching-Adjusted Indirect Comparison
Immunotherapy
Oncology
Allergy
Immunology
